EXHIBIT 8.1
At 31 December 2007 | Country | Percentage of voting share capital held | Principal activity | ||
UK | |||||
AstraZeneca UK Limited | England | 100 | (1) | Research and development, manufacturing, marketing | |
AstraZeneca Reinsurance Limited | England | 100 | Insurance and reinsurance underwriting | ||
AstraZeneca Treasury Limited | England | 100 | Treasury | ||
Continental Europe | |||||
NV AstraZeneca SA | Belgium | 100 | Manufacturing, marketing | ||
AstraZeneca Dunkerque Production SCS | France | 100 | Manufacturing | ||
AstraZeneca SAS | France | 100 | Research, manufacturing, marketing | ||
AstraZeneca GmbH | Germany | 100 | Development, manufacturing, marketing | ||
AstraZeneca Holding GmbH | Germany | 100 | Manufacturing, marketing | ||
AstraZeneca SpA | Italy | 100 | Manufacturing, marketing | ||
AstraZeneca Farmaceutica Spain SA | Spain | 100 | Manufacturing, marketing | ||
AstraZeneca AB | Sweden | 100 | Research and development, manufacturing, marketing | ||
AstraZeneca BV | The Netherlands | 100 | Marketing | ||
The Americas | |||||
AstraZeneca Canada Inc. | Canada | 100 | Research, manufacturing, marketing | ||
IPR Pharmaceuticals Inc. | Puerto Rico | 100 | Development, manufacturing, marketing | ||
AstraZeneca LP | US | 99 | Research and development, manufacturing, marketing | ||
AstraZeneca Pharmaceuticals LP | US | 100 | Research and development, manufacturing, marketing | ||
Zeneca Holdings Inc. | US | 100 | Manufacturing, marketing | ||
MedImmune, Inc. | US | 100 | Research and development, manufacturing, marketing | ||
Asia, Africa & Australasia | |||||
AstraZeneca Pty Limited | Australia | 100 | Development, manufacturing, marketing | ||
AstraZeneca KK | Japan | 80 | Manufacturing, marketing |
(1) Shares held directly.